Clinical trials: GLP-1
Type 1 Diabetes
Biomarkers of Heterogeneity in Type 1 Diabetes
Biomarkers of heterogeneity in type 1 diabetes: establishment of a biobank and an integrated approach to clinical and metabolic phenotyping of individuals with established T1DM.
- Trial name
- NCT04977635
- Where
- 3 sites in Netherlands
- Volunteers
- 611 people
- Sponsor
- Diabeter Nederland BV
Cystic Fibrosis
Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis
This pilot study will be conducted in adolescents with cystic fibrosis (CF) without diabetes but with abnormal glucose tolerance, and will assess the effects of sitagliptin on glucose regulation.
- Trial name
- NCT01721382
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nemours Children's Clinic
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study.
- Trial name
- NCT02402933
- Testing
- Nasal Glucagon
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Klinefelter Syndrome
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
The study seeks primarily to determine whether modulation of systemic and testicular sex steroids balance by aromatase inhibitors will positively affect the metabolic health and spermatogenesis of men with Klinefelter syndrome…
- Trial name
- KLIN-HEALTH (NCT05586802)
- Testing
- Anastrozole, Semaglutide, human chorionic gonadotropin
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- Georgios Papadakis
Lactation, Weight Loss
Effects of GLP-1 RAs on Human Lactation Outcomes
There is increasing interest in using GLP-1 Receptor Agonist (GLP-1 RA) medications after pregnancy. This study is designed to determine if these medications affect breastmilk production or the nutritional makeup of breastmilk.
- Trial name
- NCT07720414
- Testing
- Injected GLP-1 Receptor Agonists and Dual Agonists
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Insulinoma, Nesidioblastosis
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-exendin-4 in insulinoma and nesidioblastosis patients.
- Trial name
- NCT02560376
- Testing
- 68Ga-NOTA-exendin-4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Neonatal Diabetes
Effect of Food Composition on Postprandial Insulin Secretion in Neonatal Diabetes
Neonatal diabetes is diagnosed before 6 months of age and causes high blood glucose levels due to the pancreas not secreting insulin. Neonatal diabetes can be caused by a change in a DNA region called the KCNJ11 gene.
- Trial name
- FoND (NCT02921906)
- Testing
- High protein meal, High carbohydrate meal, Paracetamol
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Obesity, Childhood
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head.
- Trial name
- GLOW (NCT06977438)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 1,020 people
- Sponsor
- University of Minnesota
Type 1 Diabetes
A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years.
- Trial name
- RescuiNGkids (NCT04992312)
- Testing
- Glucagon Nasal Powder [Baqsimi]
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Chronic Liver Disease
Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases
1. Objectives 1. To test whether Ursodeoxycholic Acid (UDCA) increases Glucagon-like peptide-1 (GLP-1) response to nutrients and improves glycemic control in people with type 2 diabetes. 2.
- Trial name
- NCT01337440
- Testing
- UDCA, Sitagliptin
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Kanazawa University
Type 1 Diabetes
The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improve glycemic control vs.
- Trial name
- NCT02105324
- Testing
- Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes
Incretin-based Therapy in Early Diagnosed Type 1 Diabetes
The main objective of the trial is to study whether daily treatment with liraglutide improves insulin secretion and reduces the requirement of exogenous insulin, and whether liraglutide treatment is tolerable and safe in subjects…
- Trial name
- NCT02908087
- Testing
- Victoza® (liraglutide)
- Where
- 4 sites in Finland, Sweden
- Volunteers
- 13 people
- Sponsor
- University of Oulu
Cystic Fibrosis-related Diabetes
Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes
The current study is designed to test the feasibility of the a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults and children…
- Trial name
- NCT03258853
- Testing
- Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes
Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus
To study the effects of GLP 1 analogues and DPP 4 inhibitors on newly detected type 1 diabetes patients.
- Trial name
- NCT01235819
- Testing
- Insulin, Sitagliptin, Exenatide
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Command Hospital, India
Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying
GLP_1 RA Ultrasound Study
The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.
- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes
- Trial name
- NCT06581120
- Testing
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Hypoglycemia
Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic Mothers
Thesis Infants of diabetic mothers are at high risk to develop hypoglycemia after birth. After birth, glucose and ketone bodies are the main substrates of brain energy.
- Trial name
- NCT00434772
- Testing
- glucagon
- Where
- Israel
- Sponsor
- Shaare Zedek Medical Center
Obesity & Overweight
Stanford Pediatric Healthy Weight Index
This study will develop a simple index to measure how well the body uses insulin and overall heart and metabolic health in children and teens with obesity.
- Trial name
- NCT07316816
- Testing
- Remote Monitoring Program
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
Congenital Hyperinsulinism
Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity
The purpose of this study is to examine the effects of exendin-(9-39) on fasting blood glucose and protein induced hypoglycemia on subjects with Congenital Hyperinsulinism.
- Trial name
- NCT00897676
- Testing
- Exendin-(9-39)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Diva De Leon
Adolescence Obesity
Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents
This is a Phase Ib, randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Efsubaglutide Alfa Injection following multiple-dose…
- Trial name
- NCT07693426
- Testing
- Efsubaglutide Alfa 5 mg QW, Efsubaglutide Alfa 10 mg QW, Efsubaglutide Alfa 20 mg QW
- Where
- 5 sites in China
- Volunteers
- 36 people
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Periodontal Disease, Obesity & Overweight
Effect of GLP-1 Receptor Agonists on Periodontal Health and Response to Nonsurgical Periodontal Therapy
This study aims to evaluate the effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use on periodontal health and the response to non-surgical periodontal therapy in individuals with obesity and periodontitis.
- Trial name
- GLP1-PERIO (NCT07770906)
- Testing
- non-surgical periodontal therapy
- Volunteers
- 40 people
- Sponsor
- Cukurova University